Published Date: 08 Mar 2023
Everything will be done better if it depends on engineering. Quality management and the best results will complement scientific research, within reach and make our environment.
Read Full NewsPrime Minister Keir Starmer said on Wednesday that Britain's biggest company AstraZeneca would invest 300 million pounds ($405 million) in the country, after pausing...
In patients with active RA, switching to upadacitinib after failure of a single TNF inhibitor is more effective in reducing disease activity at 12 weeks than using a second TNF inhibitor adalimumab.
Dr Chu-Yueh Guo discusses promising MS trial results, including a study of fenebrutinib and positive safety data for ocrelizumab in pregnancy and pediatric patients.
Wearables can flag AF and capture symptoms in real time — but who truly benefits? Cardiologist Walid Amara, MD, outlines where smartwatches fit in clinical practice.
Dr Bishal Gyawali unpacks the FDA’s decision to deny RP-1 in melanoma, exploring why single-arm data and confounded response rates failed to meet the bar for clinical evidence.
Experts review the differential diagnosis of suspected IPF, highlighting how a multidisciplinary approach confirmed the diagnosis and informed selection of optimal antifibrotic therapy.
Sypres.io continuously tracks and evaluates psychedelic research, offering an up-to date view of study findings, design, and limitations.
1.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
2.
One possible target in acute myeloid leukemia is the reductive carboxylation of glutamine.
3.
Ultrasonography of hepatocellular carcinoma: From diagnosis to prognosis
4.
Discovery of a new biomarker for early detection of bladder cancer in both dogs and humans
5.
Second Malignancy Risk With CAR T-Cell Therapy on Par With Other Treatments
1.
Tumor Evolution: Signaling, Cancer Cell Plasticity, and Intratumor Heterogeneity
2.
Cardio-Oncology in Survivors: Safeguarding Hearts Through Multidisciplinary Care
3.
Oncology Drug Trends 2025: FDA Approvals, Immuno-Oncology, and Clinical Trial Insights
4.
The Silent Danger of Hematoma: How to Identify and Treat This Potentially Serious Condition
5.
Real-World Oncology Insights: CAR-T, Immunotherapy, PROs, and Digital Tools
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation